Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

57

Enrollment

NIH

Sponsor class

Conditions

Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Triple-Negative Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma

Interventions

DRUG: BET Bromodomain Inhibitor ZEN-3694
PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Nab-paclitaxel
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)